Back to Search
Start Over
Primary CNS lymphoma in children and adolescents: a descriptive analysis from the International Primary CNS Lymphoma Collaborative Group (IPCG)
- Source :
- Clinical Cancer Research, Clinical Cancer Research, American Association for Cancer Research, 2011, 17 (2), pp.346-52. ⟨10.1158/1078-0432.CCR-10-1161⟩
- Publication Year :
- 2011
- Publisher :
- HAL CCSD, 2011.
-
Abstract
- Purpose: To describe the demographic and clinical features and outcomes for children and adolescents with primary CNS lymphoma (PCNSL). Experimental Design: A retrospective series of children and adolescents with PCNSL was assembled from 10 cancer centers in 3 countries. Results: Twenty-nine patients with a median age of 14 years were identified. Sixteen (55%) had Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 1 or greater. Frontline therapy consisted of chemotherapy only in 20 patients (69%), while 9 (31%) had chemotherapy plus cranial radiotherapy. Most patients received methotrexate (MTX)-based regimens. Overall response rate was 86% (complete remission 69%, partial remission 17%). The 2-year progression-free survival (PFS) and overall survival (OS) rates were 61% and 86%, respectively; the 3-year OS was 82%. Univariate analyses were conducted for age (≤14 vs. >14 years), PS (0 or 1 vs. >1), deep brain lesions, MTX dose, primary treatment with chemotherapy alone, intrathecal chemotherapy, and high-dose therapy. Primary treatment with chemotherapy alone was associated with better overall response rates with an odds ratio (OR) of 0.125 (P = 0.02). There was a marginally significant relationship between higher doses of MTX and response (OR = 1.5, P = 0.06). ECOG-PS of 0 to 1 was the only factor associated with better outcome with hazard ratios of 0.136 (P = 0.017) and 0.073 (P = 0.033) for PFS and OS, respectively. Conclusion: This is the largest series collected of pediatric PCNSL. The outcome of children and adolescents seems to be better than in adults. PS of 0 to 1 is associated with better survival. Clin Cancer Res; 17(2); 346–52. ©2011 AACR.
- Subjects :
- Oncology
Male
Cancer Research
Lymphoma
medicine.medical_treatment
MESH: Central Nervous System Neoplasms
Central Nervous System Neoplasms
0302 clinical medicine
MESH: Child
Antineoplastic Combined Chemotherapy Protocols
Young adult
Child
MESH: Treatment Outcome
Univariate analysis
Hazard ratio
3. Good health
MESH: Antineoplastic Combined Chemotherapy Protocols
Treatment Outcome
MESH: Young Adult
030220 oncology & carcinogenesis
Child, Preschool
Female
medicine.medical_specialty
Adolescent
[SDV.CAN]Life Sciences [q-bio]/Cancer
Article
03 medical and health sciences
Young Adult
Internal medicine
medicine
Humans
Retrospective Studies
MESH: Adolescent
Chemotherapy
MESH: Humans
Performance status
business.industry
MESH: Child, Preschool
Cancer
Retrospective cohort study
MESH: Retrospective Studies
Odds ratio
medicine.disease
MESH: Male
Surgery
business
MESH: Lymphoma
MESH: Female
030217 neurology & neurosurgery
Subjects
Details
- Language :
- English
- ISSN :
- 10780432 and 15573265
- Database :
- OpenAIRE
- Journal :
- Clinical Cancer Research, Clinical Cancer Research, American Association for Cancer Research, 2011, 17 (2), pp.346-52. ⟨10.1158/1078-0432.CCR-10-1161⟩
- Accession number :
- edsair.doi.dedup.....4f8021b2359e4f27d6177221b38879a3
- Full Text :
- https://doi.org/10.1158/1078-0432.CCR-10-1161⟩